Equity Details
Price & Market Data
Price: $8.88
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $1,122,677,120
Daily Volume: 0
Performance Metrics
1 Week: 0.57%
1 Month: 7.97%
3 Months: -9.94%
6 Months: -27.55%
1 Year: 8.23%
YTD: -31.25%
About Neuren Pharmaceuticals Limited (NURPF)
Track Neuren Pharmaceuticals Limited (NURPF)'s latest movements. Priced at 8.88, the stock has a daily change of $0.00 / 0.00%. Its market cap stands at 1,122,677,120. Gain insights from its 1-year performance (8.23%) and YTD results.
Details
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Hawthorn East, Australia.